What is Cassidy Bio?
Cassidy Bio operates at the intersection of artificial intelligence and molecular biology, providing bespoke solutions designed to optimize gene editing therapeutic development. The company's core value proposition lies in its ability to empower research teams with high-precision predictive platforms for guide RNA design. By integrating sophisticated AI tools with rigorous laboratory testing, Cassidy Bio enhances decision-making throughout the entire therapeutic lifecycle. This dual-pronged strategy not only improves the safety and efficacy of gene-editing applications but also provides comprehensive off-target assessments, effectively mitigating clinical risks associated with traditional development methodologies.
How much funding has Cassidy Bio raised?
Cassidy Bio has raised a total of $8M across 1 funding round:
Seed
$8M
Seed (2025): $8M with participation from 10d, Merck, Ahren Innovation Capital, AstraZeneca, and lool Ventures
Key Investors in Cassidy Bio
Ahren Innovation Capital
Ahren Innovation Capital is an investment institution focused on supporting transformational companies at the intersection of deep technology and deep science, with a specific interest in genetics and platform technologies.
Merck
Merck & Co., Inc. is a global healthcare leader delivering innovative solutions through prescription medicines, biologic therapies, and vaccines.
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in oncology and biopharmaceuticals.
What's next for Cassidy Bio?
With this major enterprise-level funding, Cassidy Bio is well-positioned to expand its operational footprint and deepen its technological moat. The strategic roadmap likely involves scaling its AI infrastructure to handle increasingly complex genomic datasets and broadening its collaborative efforts with major pharmaceutical partners. By focusing on the rapid delivery of actionable insights, the company aims to shorten the time-to-market for next-generation gene therapies. Future growth will be defined by the firm's ability to maintain its competitive edge in predictive accuracy while navigating the complex regulatory and clinical environments inherent in the biotech sector. The backing from industry-leading institutional investors provides not only the necessary capital but also the strategic guidance required to navigate the transition from a research-focused entity to a commercial-stage powerhouse in the gene-editing space.
See full Cassidy Bio company page
